New Study on Sodium Butyrate and Non-Alcoholic Fatty Liver Disease

Overview of Non-Alcoholic Fatty Liver Disease

A recent article published in the British Journal of Nutrition highlights the potential of oral sodium butyrate (SoB) supplementation in protecting mice from the early stages of non-alcoholic fatty liver disease (NAFLD). NAFLD has emerged as one of the most prevalent liver diseases globally, encompassing a range of conditions from mild hepatic inflammation to severe complications such as steatohepatitis and liver cirrhosis.

Contributing Factors to NAFLD

The precise mechanisms behind NAFLD remain poorly understood; however, several known risk factors contribute to its development. Insulin resistance is frequently cited as a primary cause, alongside chronic hypertension, metabolic syndrome, hypertriglyceridemia, and significant fluctuations in weight. Recent research has also identified alterations in gut barrier function, which may lead to increased absorption of intestinal bacterial endotoxins, as a significant factor in NAFLD progression.

Current Treatment Approaches

While gradual weight loss, management of diabetes and hypertension, and vitamin E supplementation for specific patient groups are recommended strategies for NAFLD management, a definitive treatment remains elusive.

Research on Sodium Butyrate

Investigations into the protective capabilities of sodium butyrate (SoB) supplementation in animal models have shown promising results. This oral supplement has been found to enhance intestinal permeability, thereby shielding the liver from intestinal bacterial endotoxins.

Study Details and Methodology

The study published in the British Journal of Nutrition examined the molecular mechanisms underlying the protective effects of SoB against NAFLD. Conducted on six-week-old male mice, the research involved three groups: a control group, a group on a fructose-enriched diet, and a group on a fructose-enriched diet supplemented with sodium butyrate. Key markers, including liver damage, intestinal barrier function, glucose metabolism, toll-like receptor-4 (TLR-4) activity, and melatonin signaling, were assessed. Additionally, differentiated human carcinoma colon-2 cells (Caco-2) were analyzed to evaluate the effects of oral intake on intestinal cell behavior.

Results and Implications

The findings indicated that, while SoB supplementation did not significantly affect markers of intestinal function, glucose metabolism, or body weight, it substantially decreased triglyceride accumulation and inflammation in the liver. Moreover, treatment with SoB led to increased melatonin levels and enhanced expression of enzymes involved in melatonin synthesis in both duodenal tissue and Caco-2 cells. The results suggest a link between SoB, melatonin levels in duodenal cells, and the attenuation of NAFLD development in mice.

Future Research Directions

Given the study’s outcomes, the authors recommend further research to explore the effects of sodium butyrate on NAFLD in human subjects.

Reference

Jin CJ, Sellmann C, Engstler AJ, Ziegenhardt D, Bergheim I. Supplementation of sodium butyrate protects mice from the development of non-alcoholic steatohepatitis (NASH). British Journal of Nutrition. 2015;114(11):1745-1755. doi:10.1017/S0007114515003621.